Meeting
2022 ASCO Annual Meeting
NGS analysis of germline mutation profile of patients with hepatocellular carcinoma in China.
Authors
Xiaobing Wu
Eastern Hepatobiliary Surgery Hospital, Shanghai, China
Xiaobing Wu , Didi Guo , Tiantian Han , Yaping Zhao , Juan Ma , Guanghua Lu , Fanfeng Bu , Siqi Chen , Wanglong Deng , Ran Ding
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Germline Genetic Testing
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 10585)
DOI
10.1200/JCO.2022.40.16_suppl.10585
Abstract #
10585
Poster Bd #
460
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Analysis of ATM germline mutations in solid tumors from Chinese patients.
First Author: Tao Fu
Poster
2023 ASCO Genitourinary Cancers Symposium
A cohort study evaluating the clinical, environmental and genetic profiles of men with early-onset, aggressive prostate cancer.
First Author: Sarah Elizabeth Fenton
Poster
2022 ASCO Annual Meeting
Next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA) in patients (pts) with advanced hepatocellular carcinoma (HCC).
First Author: Darren Cowzer
Poster
2022 ASCO Annual Meeting
Germline predisposition in oncologic and dermatologic melanoma cohorts.
First Author: Pauline Funchain